Related Experiment Videos
Antiglutamate therapy of ALS--which is the next step?
A C Ludolph1, T Meyer, M W Riepe
1Department of Neurology, University of Ulm, Federal Republic of Germany.
Abstract:
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which was thought to be untreatable for a long time. However, recent evidence in men indicates that antiglutamatergic strategies are the first to have an influence on its pathogenesis and slow down the disease process. Since the effect of the drugs is still small, this progress cannot only be seen as a success of the present but most also be acknowledged as a starting point for the future. How will these future studies look like? They will have to take into account that ALS presumably has a long preclinical period and they will use a number of novel compounds and treatment strategies which have recently been shown to be effective in a transgenic animal model. This also implies that we are likely to use combination therapies and have to try to treat patients early. The latter will be necessarily connected with the demand for a novel clinical attitude to the diagnosis of the disease.
Insights
Antiglutamatergic strategies show promise in slowing amyotrophic lateral sclerosis (ALS) progression. Future research will focus on combination therapies and early intervention, acknowledging the disease's long preclinical phase.
Area of Science:
- Neurodegenerative diseases
- Neurology
- Drug discovery
Background:
- Amyotrophic lateral sclerosis (ALS) was historically considered untreatable.
- Recent findings in male patients suggest antiglutamatergic strategies impact ALS pathogenesis.
- Current therapeutic effects are modest, highlighting the need for further advancements.
Purpose of the Study:
- To review the current state of amyotrophic lateral sclerosis (ALS) treatment.
- To outline future directions for ALS research and therapy.
- To emphasize the importance of early diagnosis and novel treatment strategies.
Main Methods:
- Review of recent evidence on antiglutamatergic strategies in ALS.
- Discussion of findings from transgenic animal models.
- Consideration of combination therapies and early intervention approaches.
Main Results:
- Antiglutamatergic strategies represent a first step in influencing ALS pathogenesis.
- Current treatments offer limited but significant disease modification.
- Novel compounds and strategies show promise in preclinical models.
Conclusions:
- ALS treatment is evolving beyond its previously untreatable status.
- Future ALS therapies will likely involve combination treatments and early intervention.
- A paradigm shift in clinical diagnosis is needed to facilitate early treatment.